Journal overview

Journal of Medical Economics is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers in the pharmacoeconomics and healthcare research community.  

Journal of Medical Economics aims to help translate research advances into patient care and lead in transparency/disclosure. The journal publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience.

Journal of Medical Economics also specializes in the publication of studies that determine the effectiveness of medical treatment, involving measurements of therapeutic and/or preventative outcomes. Methods employed in the studies commonly involve sets of patients with comparable clinical characteristics and include measurements of mortality, morbidity and patient-reported outcomes (including the patient’s quality of life, functional status and satisfaction with healthcare).

Articles focus on the following key areas:

  • Economic analyses (in the form of cost minimization, cost effectiveness, cost utility, cost benefits, cost consequence, cost of illness, burden of disease)
  • Health economics methodology
  • Discussions on policy issues
  • Resource utilization studies
  • Disease management
  • Modelling studies
  • Meta-analyses of randomized controlled trials, outcomes and clinical trials data


All manuscripts submitted to the journal are peer-reviewed in a single-blind fashion. Authors can choose to publish gold open access in this journal.

Read the Instructions for Authors for information on how to submit your article.

 

*Please note that Journal of Medical Economic converted to a fully Open Access journal beginning with Volume 24 (2021). The 1998-2020 volumes will be free to access from 1 January 2021.

Read full aims and scope

Latest issues

Previous issue

Cover image for Journal of Medical Economics, Volume 25, Issue sup1
Volume 25, Issue sup1, 2022

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations